Subcutaneous Implants of a Cholesterol-Triglyceride-Buprenorphine Suspension in Rats

Table 1

Dose, analyses, and histopathology schedules for TAS Trials 1 and 2.

(a) TAS Trial 1: single dose

Trial days	1	2	3	4
Anesthesia	+
Surgery	+
Drug or negative control dose	+
Hematology		+		+
Chemistry		+		+
Urinalysis		+		+
Weight		+		+
Observed AM		+	+	+
Observed PM	+	+	+
Histopathology				+

(b) TAS Trial 2: repeat dose

Trial days	1	2-3	4	5	6	7	8	9–11	12
Anesthesia	+		+				+
Surgery	+
Drug or negative control dose	+		+				+
Hematology					+				+
Chemistry					+				+
Urinalysis					+				+
Weight			+		+		+		+
Observed AM		+	+	+	+	+	+	+	+
Observed PM	+	+	+	+	+	+	+	+
Histopathology									+